Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E27.32 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.60B Perf Week-0.72%
Market Cap196.30B Forward P/E15.04 EPS next Y5.02 Insider Trans0.12% Shs Float2.53B Perf Month-7.91%
Income6.67B PEG4.53 EPS next Q1.19 Inst Own10.00% Short Float0.15% Perf Quarter-9.49%
Sales49.78B P/S3.94 EPS this Y-33.30% Inst Trans-0.07% Short Ratio2.36 Perf Half Y-1.25%
Book/sh30.43 P/B2.48 EPS next Y6.33% ROA5.10% Target Price95.16 Perf Year-15.09%
Cash/sh- P/C- EPS next 5Y6.03% ROE9.10% 52W Range68.87 - 90.07 Perf YTD-8.78%
Dividend2.72 P/FCF98.99 EPS past 5Y-7.50% ROI7.80% 52W High-16.13% Beta0.68
Dividend %3.60% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.00% 52W Low9.69% ATR1.00
Employees118000 Current Ratio0.90 Sales Q/Q-1.70% Oper. Margin16.90% RSI (14)33.06 Volatility0.70% 1.06%
OptionableYes Debt/Eq0.36 EPS Q/Q-0.80% Profit Margin13.60% Rel Volume1.11 Prev Close75.92
ShortableYes LT Debt/Eq0.22 EarningsOct 25 BMO Payout95.20% Avg Volume1.61M Price75.54
Recom2.30 SMA20-3.37% SMA50-5.02% SMA200-2.54% Volume1,786,844 Change-0.50%
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Oct-21-16 06:04PM  Do Analysts Expect Negative Growth for Novartis in 3Q16?
03:47PM  Whats to Be Expected from Novartiss 3Q16 Earnings?
09:43AM  Novartis May Be Too Generic
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals
08:42AM  Should You Buy Novartis (NVS) Ahead of Earnings?
08:04AM  Eli Lilly and Co.s 3Q16: Expectations for Elanco
Oct-20-16 10:21AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
09:52AM  Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?
Oct-19-16 12:39PM  Biogen Expected to Report Modest Revenue Growth in 3Q16
06:30AM  Trump Or Hillary? Bull Market Either Way at Forbes
Oct-17-16 06:16PM  Pfizer to launch cheaper version of J&J immune drug Remicade
Oct-14-16 11:04AM  How Much Is Pfizers Return Potential?
10:10AM  Johnson & Johnsons 3Q16 Earnings: What to Expect
Oct-13-16 04:37PM  Can These Top 5 Biotechs Climb Q3 'Wall Of Worry'? RBC Calls For Rally
04:09PM  Prothena Slammed On Politics; Could Win Eli Lilly Or Pfizer Partnership
12:03PM  WHO warns global tuberculosis fight is billions of dollars behind at MarketWatch
10:40AM  Top 5 Jefferies Big Pharma Stock Picks for Q4 at 24/7 Wall St.
08:06AM  Which Healthcare Company Is the Best Dividend Stock? at Motley Fool
Oct-11-16 04:29PM  Why Momenta Pharmaceuticals, Inc. Jumped Higher Today at Motley Fool
Oct-10-16 04:20PM  Merck Topples Bristol-Myers On Lung Cancer Drug Win
12:57PM  Merck Topples Bristol-Myers On Lung Cancer Drug Win
Oct-09-16 04:15PM  Encouraging Results For Ribociclib In Advanced Breast Cancer at Forbes
Oct-08-16 02:15AM  Novartis challenges Pfizer with strong breast cancer drug data Reuters
02:15AM  Novartis Targets Breast Cancer Drug Approval to Take on Pfizer at Bloomberg
Oct-07-16 07:26PM  3 Beaten-Up Big Pharma Stocks: Are They Bargains Now? at Motley Fool
Oct-06-16 08:15PM  New CAR-T Cell Therapy May Cure Tumors (JUNO, KITE) at Investopedia
02:37PM  Novartis AG (NVS) Relocates NITD To California at Insider Monkey
01:15PM  Merck & Co. Inc. (MRK) Shuts Down Florida Facility at Insider Monkey
08:12AM  Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good
06:54AM  Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit
Oct-05-16 04:04PM  Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis
09:36AM  Novartis reshapes research, closes some Swiss, Chinese units
07:42AM  Novartis closes Swiss, Chinese centres in research revamp
03:20AM  [$$] Novartis to shift Singapore research facility at Financial Times
Oct-03-16 12:44PM  Novartis Is Surviving
09:48AM  Friends or Foes: Amgen and Novartis (AMGN, NVS) at Investopedia
Oct-02-16 05:00AM  Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters
Oct-01-16 01:15AM  Novartis psoriasis drug maintains efficacy after 4 years - study Reuters
Sep-30-16 04:54PM  Prothena Builds On Psoriasis Science For Arthritis Treatment
11:05AM  Which Pfizer Products Reported Declining Sales?
07:10AM  SQZ Biotech nabs $16M funding, hires former Novartis exec at
Sep-29-16 06:04PM  The Pfizer-Anacor Deal: A Review
04:09PM  Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market
10:03AM  7 Healthcare Stocks in Focus on World Heart Day
07:49AM  5 Big Breakout Trades You Should Have in Your Portfolio This Fall
Sep-28-16 11:05AM  Tevas Commercial Strategy May Be Successful across Europe
08:06AM  Teva Pharmaceutical Still Dominates the Generic Market in Europe
Sep-27-16 04:20PM  Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval
10:28AM  Kite Pharma Reports Favorable Data from Lymphoma Study
10:04AM  This Strategy Could Boost Tevas Growth Prospects Even More
09:42AM  Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19
09:24AM  Why Kite Pharma's Stock Is Soaring Today at Motley Fool
Sep-26-16 11:11AM  ETFs with exposure to Novartis AG : September 26, 2016
11:05AM  Winning? We Review How Teva Dominates Generic Drug Space
09:33AM  The Internet of Medical Things: 6 Stocks in Focus
09:18AM  Novartis Ilaris Approved for Extended Use in Periodic Fever
Sep-23-16 05:25PM  Tevas Valuation Multiples Compared to Other Generic Drug Players
01:09PM  Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions PR Newswire
10:01AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
07:29AM  UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure Reuters
Sep-22-16 04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
02:00PM  A Double Dose of Trouble at Novartis
01:05PM  Does Novartis AG (NVS) Have The Solution For Malaria? at Insider Monkey
Sep-20-16 11:04AM  Teva, Eli Lilly Have Migraine Treatments in Trial Phases
10:46AM  Breaking the mould: GSK picks Big Pharma's first female CEO
10:15AM  Novartis A Buy At Chardan
10:05AM  Alder BioPharmaceuticalss Migraine Therapy Shows Promise
08:05AM  Entering Migraine Market Wont Be Easy for Novartis, Amgen
06:50AM  Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing
05:52AM  Coverage initiated on Novartis AG by Chardan Capital Markets
Sep-19-16 10:16AM  Novartis (NVS) Presents Positive Data on Cardiovascular Drug
Sep-17-16 11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
11:00AM  Novartis says MS drug cut risk of disability advance in study Reuters
05:00AM  Novartis Drug for Multiple Sclerosis Shows Reduction in Risks at Bloomberg
Sep-16-16 12:09PM  Novartis says experimental drug helps chronic migraine sufferers
09:21AM  Novartis Reports Positive Phase II Data on Migraine Drug
06:00AM  An Attractive European Stock ETF at Morningstar
Sep-14-16 07:00AM  Our Ultimate Stock-Pickers Top 10 Dividend-Yielding Stocks at Morningstar
Sep-13-16 01:36PM  Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
10:25AM  Jefferies Issues Top Pharma and Biohealth Stocks to Buy at 24/7 Wall St.
10:04AM  GlaxoSmithKline Giving a Shot to Its Vaccines Business
08:04AM  Performance of GSKs Global Pharmaceuticals Franchises Mixed
Sep-12-16 04:36PM  This Firm Wins Battle Against Glaucoma By Putting A Stick In Your Eye
10:04AM  How Can Pfizer Revive Its Essential Health Business?
10:04AM  Whats the Problem with GSKs Pharmaceutical Segment?
09:54AM  The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working at Motley Fool
08:05AM  Of GSKs Business Segments, This One Is the Sales Laggard
Sep-11-16 05:09PM  Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
11:53AM  This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It at Motley Fool
Sep-09-16 01:11PM  Will These Cancer Therapies Pay Off? (KITE, JUNO) at Investopedia
10:24AM  3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August at Motley Fool
Sep-07-16 05:44PM  Europe: New safe haven?
05:24PM  GW Pharmaceuticals Stock Pops On Report Of Buyout Interest
09:17AM  Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
Sep-06-16 12:23PM  Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever
10:26AM  Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids
09:38AM  Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Sep-05-16 08:04AM  Incytes Product Portfolio Includes Potentially Lucrative Drugs
Sep-04-16 02:05PM  How Google Plans to Reinvent Healthcare at Motley Fool
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM